The 5-alpha reductase inhibitor finasteride reduces dyskinesia in a rat model of Parkinson's disease.
Frau, Roberto
The 5-alpha reductase inhibitor finasteride reduces dyskinesia in a rat model of Parkinson's disease. [electronic resource] - Experimental neurology 05 2017 - 1-7 p. digital
Publication Type: Journal Article; Research Support, Non-U.S. Gov't
1090-2430
10.1016/j.expneurol.2017.01.012 doi
5-alpha Reductase Inhibitors--therapeutic use
Adrenergic Agents--toxicity
Animals
Antiparkinson Agents--adverse effects
Benserazide--adverse effects
Disease Models, Animal
Dose-Response Relationship, Drug
Dyskinesia, Drug-Induced--drug therapy
Female
Finasteride--therapeutic use
Functional Laterality--drug effects
Levodopa--adverse effects
Male
Oxidopamine--toxicity
Parkinson Disease--drug therapy
Psychomotor Disorders--chemically induced
Rats
Rats, Sprague-Dawley
Time Factors
Tyrosine 3-Monooxygenase--metabolism
The 5-alpha reductase inhibitor finasteride reduces dyskinesia in a rat model of Parkinson's disease. [electronic resource] - Experimental neurology 05 2017 - 1-7 p. digital
Publication Type: Journal Article; Research Support, Non-U.S. Gov't
1090-2430
10.1016/j.expneurol.2017.01.012 doi
5-alpha Reductase Inhibitors--therapeutic use
Adrenergic Agents--toxicity
Animals
Antiparkinson Agents--adverse effects
Benserazide--adverse effects
Disease Models, Animal
Dose-Response Relationship, Drug
Dyskinesia, Drug-Induced--drug therapy
Female
Finasteride--therapeutic use
Functional Laterality--drug effects
Levodopa--adverse effects
Male
Oxidopamine--toxicity
Parkinson Disease--drug therapy
Psychomotor Disorders--chemically induced
Rats
Rats, Sprague-Dawley
Time Factors
Tyrosine 3-Monooxygenase--metabolism